ArticleMolecular medicine reports2018
EGFR mutations subset in Chinese lung squamous cell carcinoma patients.
Article in Molecular medicine reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Therapeutic Impact of Third-generation Tyrosine Kinase Inhibitors on Lung Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Mutations: A Case Description and Systematic Literature Review.Internal medicine (Tokyo, Japan) · 2026Pooled it
- The role of the tumor microenvironment in drug resistance acquisition in lung squamous cell carcinoma.Journal of experimental & clinical cancer research : CR · 2026Review
- Article
- Macrophage-Mediated Cellular Communication Networks in Lung Squamous Cell Carcinoma and Adenocarcinoma Revealed by Single-Cell Sequencing.Mediators of inflammation · 2026Article
- Artificial base mismatches-mediated PCR (ABM-PCR) for detecting clinically relevant single-base mutations.Clinical chemistry and laboratory medicine · 2025Article
- [A Case Report of EGFR-TKIs Resistant Secondary MET Gene Amplified Lung Squamous Cell Carcinoma and Literature Review].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- Characterization of prognostic signature related with twelve types of programmed cell death in lung squamous cell carcinoma.Journal of cardiothoracic surgery · 2024Article
- Article
- [Advances of Molecular Targeted Therapy in EGFR-mutated Squamous Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- Article
- Kallikrein-related peptidase 13 expression and clinicopathological features in lung squamous cell carcinoma.Molecular and clinical oncology · 2023Article
- Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials.Signal transduction and targeted therapy · 2022Review
- Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients withCurrent oncology (Toronto, Ont.) · 2022Review
- Treatment outcomes and safety of afatinib in advanced squamous cell lung cancer progressed after platinum-based doublet chemotherapy and immunotherapy (SPACE study).Thoracic cancer · 2021Article
- Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective Study.Frontiers in oncology · 2021Article
- Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma.Thoracic cancer · 2020Article
- Identification of potential diagnostic and therapeutic target genes for lung squamous cell carcinoma.Oncology letters · 2019Article
- Development and validation of a model to predict tyrosine kinase inhibitor-sensitive EGFR mutations of non-small cell lung cancer based on multi-institutional data.Thoracic cancer · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Research has identified that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) possess large benefits for adenocarcinoma (ADC), although little benefit for squamous cell carcinoma (SCC). The aim of the present study was to investigate the percentage of patients with SCC with the EGFR mutations subset and the benefits of EGFR TKIs in SCC. In the present study, the EGFR mutations subset was detected with an amplification refractory mutation system in 1,359 clinical SCC tissues. The association of the EGFR mutations subset with clinicopathological parameters was evaluated using the Mann‑Whitney U test, and Kruskal‑Wallis H. Kaplan‑Meier survival analysis was used to estimate the effect of the EGFR mutations subset on SCC patient survival rates. A total of 94 out of 1,359 SCC patients were identified as having EGFR mutations, an EGFR mutation rate of 6.92%. The EGFR mutations subset in the 94 cases was identified as follows: 37.2% (35/94) in exon 19; 39.4% (37/94) in L858R; 5.3% (5/94) in T790M; 4.3% (4/94) in G719X; 2.1% (2/94) in L861Q; and 11.7% (11/94) in other mutations. Kaplan‑Meier survival analysis identified that the differentiation, pathological tumor, node, metastasis stage, lymph node metastasis and distant metastases were significantly associated with patients' survival (P>0.05; log‑rank test), and no significant difference was observed between TKI therapy and chemotherapy in terms of patient survival rates (P>0.05). In addition, the overall discordant rate of the EGFR mutations subset in SCC patients was relatively low. Due to the non‑significant difference between TKI therapy and chemotherapy in terms of patient survival and the lower discordance rate of the EGFR mutations subset in SCC patients, EGFR TKIs could be a recommended treatment for SCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.